相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome Analysis of the dal-Outcomes Randomized Clinical Trial
Gregory G. Schwartz et al.
JAMA CARDIOLOGY (2018)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Peter Willeit et al.
LANCET (2018)
Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score
Roland Klingenberg et al.
EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE (2018)
Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acutemyocardial injury improves risk stratification after acute coronary syndromes
Roland Klingenberg et al.
EUROPEAN HEART JOURNAL (2017)
Lipoprotein(a): the revenant
Baris Gencer et al.
EUROPEAN HEART JOURNAL (2017)
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN
Rishi Puri et al.
ATHEROSCLEROSIS (2017)
Prognostic value of PCSK9 levels in patients with acute coronary syndromes
Baris Gencer et al.
EUROPEAN HEART JOURNAL (2016)
Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes
David Nanchen et al.
CIRCULATION (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study
Rutger Verbeek et al.
JOURNAL OF LIPID RESEARCH (2016)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Structure, function, and genetics of lipoprotein (a)
Konrad Schmidt et al.
JOURNAL OF LIPID RESEARCH (2016)
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role
Frederick J. Raal et al.
JOURNAL OF LIPID RESEARCH (2016)
Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS)
Mehdi Afshar et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes
Baris Gencer et al.
ATHEROSCLEROSIS (2015)
Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes
David Nanchen et al.
EUROPEAN HEART JOURNAL (2015)
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
Sotirios Tsimikas et al.
LANCET (2015)
Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
Michelle L. O'Donoghue et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Frederick J. Raal et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
A catalogue of reporting guidelines for health research
I. Simera et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2010)
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Pia R. Kamstrup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Effect of acute myocardial infarction on cholesterol ratios
N Wattanasuwan et al.
CHEST (2001)
分享论文
